

News Release



Unisys Research on Trustworthy AI

Published in Frontiers in Pharmacology Journal

Peer-reviewed study explores how neurosymbolic AI can improve trust and explainability with emerging technologies in healthcare and other regulated industries

BLUE BELL, Pa., Sept. 2, 2026 – [Unisys](#) (NYSE: UIS) announces the publication of its peer-reviewed research paper, “[From benchmark accuracy to pharmacological credibility: why mechanistic explainability must define the next generation of AI for drug repurposing](#),” in Frontiers in Pharmacology, a leading journal from [Frontiers Media](#). The study explores one of the most significant barriers to AI adoption in healthcare and other regulated industries: the need for clear visibility into how AI systems generate recommendations to validate and trust their outputs.

Many AI systems can generate outputs but cannot clearly explain how they arrived at them, making it difficult for organizations to evaluate and trust the results. To address this challenge, the research explores a neurosymbolic AI approach that combines advanced AI techniques with human knowledge and reasoning to provide greater transparency into how conclusions are reached.

The paper also introduces a new framework, called MURP (Mechanistic Coherence, Uncertainty, Robustness and Provenance), which extends the evaluation of AI systems beyond predictive accuracy to include criteria needed for use in highly regulated environments.

"The next phase of AI innovation will be shaped not only by performance, but by credibility," said Salvatore Sinno, vice president of innovation, Enterprise Computing Solutions, Unisys.

"Organizations are increasingly exploring AI in complex and regulated settings, making the ability to evaluate, govern and stand behind AI-driven outcomes just as important as the outcomes themselves."

This publication further demonstrates how Unisys is advancing AI research that turns emerging capabilities into practical business value. Together with findings from the recently published [Unisys AI & Cloud Insights Report 2026](#), this work supports the company's AI-First strategy and focuses on moving organizations from experimentation to scalable, real-world adoption.

Read the published [research paper](#) in Frontiers in Pharmacology and learn more about [AI offerings](#) from Unisys.

About Unisys

Unisys is a global technology solutions company that powers breakthroughs for the world's leading organizations. Our solutions – cloud, AI, digital workplace, applications and enterprise computing – help our clients challenge the status quo and unlock their full potential. To learn how we have been helping clients push what's possible for more than 150 years, visit [unisys.com](#) and follow us on [LinkedIn](#).

Contact:

Heather Gries, Unisys

heather.gries@unisys.com

###

RELEASE NO.: 0902/10068

Unisys and other Unisys products and services mentioned herein, as well as their respective logos, are trademarks or registered trademarks of Unisys Corporation. Any other brand or product referenced herein is acknowledged to be a trademark or registered trademark of its respective holder.

UIS-C